sr141716 has been researched along with cp 945598 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, SC; Carpino, PA; DaSilva-Jardine, P; Day, R; DiBrino, J; Dow, RL; Griffith, DA; Hadcock, JR; Iredale, PA; Landis, MS; O'Connor, RE; Scott, DO | 1 |
| Erdélyi, P; Fischer, J; Gyertyán, I; Hegyi, E; Kiss, B; Laszy, J; Páyer-Lengyel, D; Szabó, G; Szemzo, A; Szikra, J; Varga, B; Vastag, M; Vukics, K | 1 |
| Bortoff, K; Fennell, T; Fulp, A; Maitra, R; Mathews, J; Seltzman, H; Snyder, R; Zhang, Y | 1 |
| Azzara, AV; Baska, RA; Behnia, K; Carlson, KE; Cullen, MJ; Devenny, JJ; Ellsworth, BA; Everlof, GG; Ewing, WR; Godonis, HE; Gu, Z; Gudmundsson, O; Harvey, SJ; Johnghar, S; Kang, L; Keim, WJ; Lee, N; Murphy, BJ; Murugesan, N; Pelleymounter, MA; Ranasinghe, A; Rohrbach, KW; Sher, PM; Sitkoff, DF; Stetsko, PI; Sulsky, RB; Thomas, MA; Wu, G; Wu, X; Yang, Y; Yu, G; Zhu, Y; Zuvich, E | 1 |
| Amato, GS; Cortes, R; Harris, DL; Lefever, TW; Maitra, R; Manke, A; Runyon, SP; Snyder, RW; Vasukuttan, V; Wang, S; Wiethe, RW; Zhang, Y | 1 |
5 other study(ies) available for sr141716 and cp 945598
| Article | Year |
|---|---|
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.
Topics: Animals; Dogs; Drug Discovery; Energy Metabolism; Fats; Oxidation-Reduction; Piperidines; Purines; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2009 |
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cattle; Drug Design; Eating; Humans; Lipids; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2009 |
Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.
Topics: Animals; Blood-Brain Barrier; Calcium; Cell Line; Cell Membrane Permeability; Dogs; Drug Design; Humans; Ligands; Male; Piperidines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship; Urea | 2012 |
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Topics: Animals; Cytochrome P-450 Enzyme System; Drug Discovery; Half-Life; Protein Binding; Pyridazines; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Triazoles | 2013 |
Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.
Topics: Alcohols; Animals; Cannabinoid Receptor Antagonists; Fatty Liver; Female; Humans; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Protein Conformation; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Tissue Distribution | 2018 |